News – Page 1172 – Endpoints News

Spark adds fresh evidence that pioneering gene therapy could be a game changer for patients

9 years ago

Bristol-Myers reels back in an early-stage cancer drug prospect in $60M Asia deal

9 years ago

Protocols: Valeant sheds assets, but falls short on consensus; What if voters got a chance to weigh in on your trial?

9 years ago

As gene therapy rivals advance, Biogen moves closer to spinning out hemophilia drugs, R&D

9 years ago

FDA clears a Phase III path for Biogen’s BACE drug for Alzheimer’s

9 years ago

Will AbbVie bite? Decision time after Ablynx's rheumatoid arthritis drug fails a key study

9 years ago

Now a two-time loser, AstraZeneca’s hopes for selumetinib dwindle after another PhIII flop

9 years ago

Racing past a wounded Juno, Kite aims to file lead CAR-T for OK by end of 2016

9 years ago

Protocols: Allergan disses giant leaps, concentrates on stepping stones; AstraZeneca also gets a boost from ...

9 years ago

Acetylon can say goodbye to buyout and a $1B-plus in Celgene biobucks

9 years ago

Novartis's asthma ‘wonder drug’ basks in the bright spotlight of a UK media frenzy

9 years ago

Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study

9 years ago

Celgene stays focused on protein homeostasis, backs Cleave’s $37M round to fuel early studies

9 years ago

Allergan, Richter steer past another late-stage pileup with cariprazine

9 years ago

Protocols: Did Ionis set out to exclude side effects? Merck takes another step forward with Lantus biosimilar

9 years ago

Woodford gets slammed with a brutal set of portfolio hits, as Northwest continues to fester

9 years ago

Thumbs Up/Thumbs Down: The new buzz in R&D, blockbuster work on a budget and why what’s dead may never die

9 years ago

Bristol-Myers craters after blockbuster checkpoint drug Opdivo fails key lung cancer study

9 years ago

Gemphire IPO staggers into the market, reaping $30M

9 years ago

Deaths derail Juno's launch countdown, giving Kite and Novartis the lead

9 years ago

Pushed by high costs in Cambridge, fast-growing Decibel makes a pioneering leap to Fenway

9 years ago

Momenta hit with a setback as pancreatic cancer drug flops in PhII

9 years ago

Regeneron makes a blockbuster case for its PhIII drug pipeline

9 years ago

BioRegnum: What’s the deal with Biogen?

9 years ago

First page Previous page 1169 1170 117111721173 1174 1175 Next page Last page